# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
https://ipsearch.ipaustralia.gov.au/patents/2017213812
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Longeveron (NASDAQ:LGVN) with a Buy and maintains $10 price ta...
Longeveron presented promising Phase 2a clinical trial data for Lomecel-B at the AAIC 2024. The trial showed the drug's saf...
LGVN: 49% | Longeveron Announced Study Results from CLEAR MIND Phase 2a Clinical Trial of Lomecel-B In Mild Alzheimer's Di...
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Longeveron (NASDAQ:LGVN) with a Buy and lowers the price target...
- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for...